ETO/AML1 (AML-M2), HEPARIN BLOOD

image not found

NABL Cap Accredited     
This test detects the ETO/AML1 (also known as RUNX1/RUNX1T1 or t(8;21)) gene fusion, a characteristic abnormality seen in Acute Myeloid Leukemia, particularly the AML-M2 subtype. Identifying this fusion helps confirm the diagnosis, assess prognosis, and guide treatment strategies. Patients with this translocation often have a favorable response to specific chemotherapy regimens. The analysis is performed on a heparin blood sample using advanced molecular techniques for accurate detection

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 4,560.00

Sample Type: Sodium Heparin Blood

Fasting Not Required


Notes: T0020

Frequently Asked Questions (FAQ's):

What does this test detect?
It identifies the ETO/AML1 (RUNX1/RUNX1T1) fusion gene associated with AML-M2.

Why is this test important?
It helps in confirming the diagnosis, predicting prognosis, and planning treatment for acute myeloid leukemia.

What sample is required?
Heparin blood is needed for the test.

Is any preparation needed?
No special preparation or fasting is required.

How is the test performed?
Through molecular methods such as RT-PCR or FISH to detect the fusion gene.

Who should undergo this test?
Patients suspected of having acute myeloid leukemia, especially AML-M2 type.

Do the results affect treatment?
Yes, the presence of this fusion is linked with better treatment outcomes and specific therapeutic approaches

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab